UA125799U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

Diagnostic method for the development of atherosclerosis, including clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography, determination of MTHFR C677T, eNOS T786C gene polymorphism in serum, endothelin content, SOM7, SRP7, SRP7 TT, 786-SS, endothelin levels> 10 ng / ml, COMP> 595 ng / ml, EWS> 6 mg / l, IL-6> 10 ng / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (AN Okorokov.

Diagnosis of diseases of internal organs. - T. 6 -S. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that along with the study of low- and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the genes methylenetetrahydrofolate reductase (MINEK C677T), nitric oxide synthase (emoz tT786C), the content of endothelin, cartilage oligomeric matrix protein (COMP), C-reactive protein (SRP), interleukin 6 (IL-6). With homozygous carriers of 677-TT, 786-SS, endothelin levels of 210 ng/ml, SOMR »595 ng/ml, SRP »b mg/l, IL-6 »10 ng/l, the development of atherosclerosis is diagnosed.

Application of the method. Upon admission, the patient is examined, low-density lipoprotein and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. Polymorphisms of MTNEK C677tT, emo tT786C genes are determined in blood serum, endothelin content is determined by the immunoenzymatic method

SOMR, SRP, IL-6. With homozygous carrier 677-TT, 786-SS, endothelin levels 210 ng/ml,

SOMR 5595 ng/ml, SRP »6 mg/l, IL-6 210 ng/l diagnose the development of atherosclerosis.

A specific example of using the method.

Patient K., 48 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. No signs of atherosclerosis were found. Gene polymorphism was determined in blood serum

MTNEK S677T and eMMoz T786S. The content of endothelin, SOMP,

SRP, IL-6. Homozygous carriers of 677-TT and 786-SS were established. Endothelin levels - 18 ng/ml,

From SOMR - 649 ng/ml, SRP -14 mg/l, IL-b - 18 ng/l. The development of atherosclerosis was diagnosed.

Arteriographic confirmation of the diagnosis was obtained only after 13 months.

Thus, the proposed method makes it possible to establish a diagnosis at the early stages of the development of the process.

Claims (1)

USEFUL MODEL FORMULA A method of diagnosing the development of atherosclerosis, which includes a clinical examination, the study of low and high-density lipoprotein cholesterol levels, arteriography, the determination of polymorphisms of the MTNEK C677tT, eMmo5z T786C genes in blood serum, the content of endothelin, SOMP, SRP, IL-6, which differs in that , that with homozygous carriers of 677-TT, 786-SS, endothelin levels of 210 ng/ml, SOMR »595 ng/ml, SRP »6 mg/l, IL-6 »10 ng/l diagnose the development of atherosclerosis.